Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin.
Rebecca DoweyJoby ColeAlfred Arthur Roger ThompsonRebecca C HullChenghao HuangJacob WhatmoreAhmed IqbalKirsty L BradleyJoanne McKenzieAllan LawrieAlison M CondliffeEndre Kiss-TothIan SabroeLynne R PrincePublished in: ERJ open research (2022)
Our findings suggest ruboxistaurin could reduce proinflammatory and tissue-damaging consequences of neutrophils during disease, and since it has completed phase III trials for other indications without safety concerns, it is a promising and novel therapeutic strategy for COVID-19.